Keros Hits $20M Milestone in Takeda Deal, Plans 25% Payout to Shareholders
KROS is trading near its 52-week low of $9.69 (6.4% above the low).
Summary
Keros Therapeutics earned a $20 million milestone payment from Takeda after dosing the first patient in the Phase 3 ELRicate trial of elritercept for anemia in myelodysplastic syndromes. The company plans to distribute 25% of the net proceeds to stockholders. This payment is part of a deal that included a $200 million upfront fee and up to $1.1 billion in milestones, plus royalties. Keros has a $281.5 million cash runway into mid-2028, and the distribution signals confidence in the balance sheet.
At the time of this announcement, KROS was trading at $10.31 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $202.3M. The 52-week trading range was $9.69 to $22.55. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.